Physician experiences with biosimilars have increased substantially in Europe over the past few years, driven by an increased policy focus, greater comfort, and regulatory guidance. These biosimilars have also provided savings for the overall health system and have played a crucial role in enhancing sustainability of this system. Several new biosimilars are expected to launch over the next five years and ensuring their optimal use will be important.

Understanding physician perspectives on biosimilars is an important part of developing a sustainable competitive market, as these perspectives drive the overall use. This report aims to understand the experience of physicians that have been utilizing biosimilars and the perspectives of physicians that will be using them for the first time in the near future. These insights were gathered through physician surveys in select European countries, and they hold lessons for stakeholders across the healthcare system on how to optimize the use of biosimilars and overcome physician concerns.